Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Wang, H.-B.
Right arrow Articles by Ljunggren, H.-G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, H.-B.
Right arrow Articles by Ljunggren, H.-G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol. 12, No. 10, 1381-1388, October 2000
© 2000 Japanese Society for Immunology

Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis

Hua-Bing Wang1, Hulun Li1, Fu-Dong Shi2,3, Benedict J. Chambers2, Hans Link1 and Hans-Gustaf Ljunggren2

1 Experimental Neurology Unit, Division of Neurology, Karolinska Institutet, Huddinge University Hospital, 14186 Stockholm, Sweden
2 Microbiology and Tumor Biology Center (MTC), Karolinska Institutet, 17177 Stockholm, Sweden

Correspondence to: H.-B. Wang

Tumor necrosis factor receptor-1 (TNFR1, CD120a) has been implicated in the pathogenesis of several experimental models of T cell-mediated autoimmune disorders, but its role in antibody-mediated autoimmune diseases has not been addressed. Experimental autoimmune myasthenia gravis (EAMG), an autoantibody-mediated T cell-dependent neuromuscular disorder, represents an animal model for myasthenia gravis in human. To investigate the role of TNFR1 in the pathogenesis of EAMG, TNFR1–/– and wild-type mice were immunized with Torpedo acetylcholine receptor (AChR) in complete Freund's adjuvant. TNFR1–/– mice failed to develop EAMG. Lymphoid cells from TNFR1–/– mice produced low amounts of Th1 (IFN-{gamma}, IL-2 and IL-12)-type cytokines, but elevated levels of Th2 (IL-4 and IL-10)-type cytokines compared with lymphoid cells of wild-type mice. Accordingly, the levels of anti-AChR IgG2 antibodies were severely reduced and the level of anti-AChR IgG1 antibodies were moderately reduced. Co-injection of recombinant mouse IL-12 with AChR in adjuvant restored T cell responses to AChR and promoted development of EAMG in TNFR1–/– mice. These results demonstrate that the TNF/TNFR1 system is required for the development of EAMG. The lack of a functional TNF/TNFR1 system can, at least in part, be substituted by IL-12 at the stage of initial priming with AChR and adjuvant.

Keywords: autoantibody, experimental autoimmune myasthenia gravis, IL-12, Th cell, tumor necrosis factor receptor-1

3 Present address: The Scripps Research Institute, IMM-23, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA

Transmitting editor: L. Steinman


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
H. Yang, E. Tuzun, D. Alagappan, X. Yu, B. G. Scott, A. Ischenko, and P. Christadoss
IL-1 Receptor Antagonist-Mediated Therapeutic Effect in Murine Myasthenia Gravis Is Associated with Suppressed Serum Proinflammatory Cytokines, C3, and Anti-Acetylcholine Receptor IgG1
J. Immunol., August 1, 2005; 175(3): 2018 - 2025.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Feferman, P. K. Maiti, S. Berrih-Aknin, J. Bismuth, J. Bidault, S. Fuchs, and M. C. Souroujon
Overexpression of IFN-Induced Protein 10 and Its Receptor CXCR3 in Myasthenia Gravis
J. Immunol., May 1, 2005; 174(9): 5324 - 5331.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. Rowin, M. N. Meriggioli, E. Tuzun, S. Leurgans, and P. Christadoss
Etanercept treatment in corticosteroid-dependent myasthenia gravis
Neurology, December 28, 2004; 63(12): 2390 - 2392.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.